Decibel Therapeutics Company

Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technology and our expertise in inner ear biology. We are leveraging our platform to advance our pipeline of preclinical gene therapy programs that are designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders.
Technology: Other
Industry: Biotechnology, Gene therapy, Medical Device, Therapeutics
Headquarters: Cambridge, Massachusetts, United States
Founded Date: 2015
Employees Number: 51-100
Funding Status: IPO
Investors Number: 16
Total Funding: 189.2M
Estimated Revenue: $10M to $50M
Last Funding Date: 2020
Last Funding Type: Series D

Visit Website
info@decibeltx.com
https://www.twitter.com/decibeltx
Register and Claim Ownership